Company news

GRI Bio, Inc. news in 2026

GRI Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

September 28, 2026

GRI Bio Featured in "Why Now" On-Demand Video Webcast

August 27, 2026

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

August 24, 2026

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

June 18, 2026

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

April 8, 2026

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

February 17, 2026

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

February 5, 2026

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

February 4, 2026

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

January 28, 2026

GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

January 26, 2026

GRI Bio Announces Reverse Stock Split

January 21, 2026

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

January 8, 2026

Decks in 2026